Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 8:17:545-554.
doi: 10.2147/JEP.S529995. eCollection 2025.

Toxicities Associated with Systemic Administration of Interleukin-6 in Wistar Albino Rats

Affiliations

Toxicities Associated with Systemic Administration of Interleukin-6 in Wistar Albino Rats

Patricia Nabisubi et al. J Exp Pharmacol. .

Abstract

Background: Interleukin-6 is a pleiotropic cytokine being explored in therapy for cancer, trauma, and inflammatory infections, albeit with limited data about its safety. The main aim of this study was to investigate the toxicities associated with systemic administration of interleukin-6 in Wistar albino rats.

Methods: Four groups of rats, each containing six (6) animals received a daily intramuscular dose of 0.3mls of normal saline, 500ng/kg of recombinant interleukin-6, 1000ng/kg of Interleukin-6, and 2000ng/kg of Interleukin-6 for 21 days. On day 22 post-treatment, rats were euthanized, and blood and body organs were collected for analysis. Blood was used to determine liver and renal function, and hematology parameters, while liver and kidney tissue sections were used for histopathological analysis.

Results: The results revealed that systemic administration of interleukin-6 for 21 days significantly decreased levels of serum creatinine (p<0.00) and serum urea (p<0.01). IL-6 administration had no demonstrable effects on liver function across treatment groups We observed a significant decrease in lymphocytes numbers (p<0.02) across treatment groups when compared to the negative control group. Platelets were significantly elevated in the 100ng/kg treatment groups as compared to the negative control and other treatment groups. Liver and kidney tissue sections for animals that received 500ng/kg of recombinant IL-10 were comparable to those of the negative control and at 1000 and 2000ng/kg, a dose-dependent increase in organ damage was evident.

Conclusion: We demonstrate that systemic administration of recombinant IL-6 at concentrations ranging between 500-1000ng/kg is well tolerated, above this concentration, dose-dependent toxicities and adverse side effects becoming evident. It would be interesting to explore long-term toxicities associated with the systemic administration of IL-6.

Keywords: Wistar albino rats; hepatotoxicity; immunotherapy; interleukin-6; nephrotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests in this work.

Figures

Figure 1
Figure 1
Transverse section through the kidney showing histopathological changes. Plate 1 (normal control group) shows a normal kidney architecture, note the renal corpuscle (Rn) deep in the cortex, the proximal convoluted tubules (T) are also clearly discernible and similar in plate 2 (500ng/kg group). Note the mild nephrotoxicity with mild disintegration of the renal tubules in the 1000ng/kg and 2000ng/kg groups. The scale bar is 25µm.
Figure 2
Figure 2
Transverse section through the liver showing histopathological changes. Plate 1 (normal control group) shows normal liver lobular architecture, note the central vein (V) with radiating hepatic cords that are very discernible and similar to plate 2 (500ng/kg group). Plate 3 (1000ng/kg group) and plate 4 (2000ng/kg group) showed mild disintegration of hepatic cords, enlarged and degenerating hepatocytes (arrowheads). The scale bar is 25µm.

Similar articles

References

    1. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295 - DOI - PMC - PubMed
    1. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007–1023. doi: 10.1016/j.immuni.2019.03.026 - DOI - PubMed
    1. Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. oncologist. 2018;23(8):943–947. doi: 10.1634/theoncologist.2018-0028 - DOI - PMC - PubMed
    1. Malara A, Abbonante V, Di Buduo CA, Tozzi L, Currao M, Balduini A. The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control. Cell Mol Life Sci CMLS. 2015;72(8):1517–1536. doi: 10.1007/s00018-014-1813-y - DOI - PMC - PubMed
    1. Reems J-A, Pineault N, Sun S. In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus Med Rev. 2010;24(1):33–43. doi: 10.1016/j.tmrv.2009.09.003 - DOI - PMC - PubMed

LinkOut - more resources